[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thin-endometrium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thin-endometrium":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100646255","phase-3-intrauterine-g-csf-infusion-for-thin-endometrium-100646255",false,"NCT07692672","Intrauterine G-CSF Infusion for Thin Endometrium","A Single-Center Randomized Controlled Trial of Intrauterine G-CSF Infusion for Improving Pregnancy Outcomes in Patients With Thin Endometrium","GIFT","Inclusion Criteria:\n\n* Female patients aged 18 to \\\u003C40 years.\n* Patients with normal ovarian function.\n* History of endometrial thickness ≤7 mm in at least one previous endometrial preparation cycle.\n* At least two good-quality embryos remaining.\n* Fewer than 3 previous embryo transfer cycles.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Uterine diseases or conditions that may affect the uterine cavity, including intramural uterine fibroids affecting the uterine cavity, severe adenomyosis, endometriosis, uterine malformation, endometrial tuberculosis, or severe untreated intrauterine adhesions.\n* Endometrial lesions, history of pelvic tumors, or previous radiotherapy or chemotherapy.\n* Known allergy to G-CSF.\n* Current participation in another clinical study.","FEMALE","18 Years","39 Years",{"count":21,"type":22},620,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Thin endometrium is a condition in which the lining of the uterus is too thin during preparation for embryo transfer. This may reduce the chance of pregnancy and live birth in patients undergoing frozen-thawed embryo transfer.\n\nThis study will evaluate whether intrauterine infusion of granulocyte colony-stimulating factor, also called G-CSF, can improve pregnancy outcomes in patients with thin endometrium. Participants will be randomly assigned to one of two groups. The experimental group will receive mild endometrial stimulation followed by intrauterine infusion of G-CSF 300 μg. The control group will receive the same mild endometrial stimulation followed by intrauterine infusion of normal saline. Both groups will then continue standard endometrial preparation for frozen-thawed embryo transfer.\n\nThe main outcome of the study is the live birth rate. The study will also assess endometrial thickness, endometrial blood flow, clinical pregnancy rate, miscarriage rate, and safety outcomes, including adverse events, pregnancy complications, fetal malformations, and neonatal birth defects. Participants will be followed from enrollment through embryo transfer, pregnancy assessment, and delivery.\n\nThis is a single-center, prospective, randomized controlled trial conducted at Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School. The planned sample size is 620 participants.",[28,29],"Thin Endometrium","Female Infertility",[28,31,32,33,34],"G-CSF","Intrauterine Infusion","Frozen-Thawed Embryo Transfer","Live Birth Rate","NOT_YET_RECRUITING","2026-07-08",{"date":38,"type":39},"2026-07-09","ACTUAL",{"date":41,"type":22},"2026-10",{"date":43,"type":22},"2029-08",{"name":45,"class":46},"Nanjing University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100611911","a-randomized-controlled-study-on-the-effect-of-mrjps-on-improving-ovarian-function-and-endometrial-receptivity-100611911","NCT07246733","A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity","Inclusion Criteria:\n\n* Fertile women, aged 20 to 45 years old, with regular and normal menstrual cycles.\n\nExclusion Criteria:\n\n* ① Allergic to royal jelly or its components; ② Suffering from severe chronic diseases or endocrine system disorders; ③ Pregnant or breastfeeding; ④ Undergoing hormone replacement therapy (HRT) within the last month",true,"20 Years","45 Years",{"count":57,"type":22},66,[59],"NA","This study will assess the effects of the rose tablet candies produced by MRJPs on the subjects, evaluate the role of MRJPs in the ovarian function and endometrial receptivity of women, reveal the potential application value of MRJPs in reproductive health, and determine its safety and effectiveness.",[62,28],"Diminished Ovarian Reserve (DOR)",[64,65,66,67],"Ovarian reserve","Endometrial receptivity","Major Royal Jelly Proteins（MRJPs）","Reproductive health","RECRUITING","2025-11-20",{"date":71,"type":39},"2025-11-24",{"date":73,"type":39},"2025-07-01",{"date":75,"type":22},"2028-07-31",{"name":77,"class":46},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":78},"100565684","application-of-platelet-rich-plasma-prp-in-reproductive-medicine-100565684","NCT06645379","Application of Platelet-rich Plasma (PRP) in Reproductive Medicine","Inclusion Criteria:\n\n* Premature ovarian insufficiency: ① Women aged \\>18 and \\\u003C40 years old; ② Oligomenorrhea or amenorrhea for more than 4 months (excluding pregnancy); ③ Basal follicle stimulating hormone (FSH) \\>25IU\u002FL (interval \\>4 weeks) at least 2 times, or total antral follicles (AFC) \\\u003C5, or anti-Mullerian hormone (AMH) \\\u003C1.1ng\u002FmL.\n* Poor ovarian response: ① Advanced age (≥40 years) or other risk factors for poor ovarian response; ② Poor ovarian response in previous IVF cycle, with ≤3 oocytes retrieved using conventional protocols; ③ Decreased ovarian reserve (antral follicle count \\\u003C5\\~7 or anti-Müllerian hormone \\\u003C0.5\\~1.1 ug\u002FL). Meeting any 2 of the above 3 criteria is sufficient.\n* Intrauterine adhesion: ① Diagnosed by hysteroscopy and scored ≥5 points according to the American Fertility Society criteria (1988); ② With symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ Adult women with the desire to conceive.\n* Thin endometium: ①Endometrial thickness \\\u003C7mm on ovulation day or on the day of human chorionic gonadotropin (HCG) injection, or \\\u003C7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive.\n* Repeated implantation failure: Women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. High-quality embryos include: Day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \\\u003C10% fragmentation) and blastocysts (≥3BB).\n\nExclusion Criteria:\n\n* Alanine aminotransferase \\> 3 times the normal upper limit or estimated glomerular filtration rate (EGFR) \\\u003C 90 ml\u002Fmin;\n* Suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs;\n* Suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors;\n* Suffering from diabetes with poor blood sugar control or other systemic diseases;\n* Drug abuse, alcoholism or drug addiction;\n* Participated in other interventional clinical studies within half a year;\n* Poor compliance;\n* Other circumstances that are not suitable for participating in the study.","50 Years",{"count":87,"type":22},300,[59],"Female fertility is affected by many factors, such as ovarian function, fallopian tube patency, uterine environment, and mental state, among which the ovaries and endometrium are more important. In reproductive medicine, ovarian dysfunction, poor ovarian reaction, intrauterine adhesion, recurrent implantation failure, and thin endometrium are the five most common diseases that affect fertility. These five diseases lack effective treatment, and previous studies have shown that platelet-rich plasma is promising in treating these five diseases, so it is necessary to further explore the therapeutic effect and potential mechanism.",[91,92,93,94,28],"Premature Ovarian Insufficiency","Intrauterine Adhesion","Poor Ovarian Response","Repeated Implantation Failure","2025-02-14",{"date":97,"type":39},"2025-02-18",{"date":99,"type":39},"2024-10-17",{"date":101,"type":22},"2027-09-15",{"name":77,"class":46}]